NewAmsterdam Pharma Company N.V. (NAMSW) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 4Aug 7Aug 12Aug 17Aug 20Aug 25Aug 31Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.7x

Market Cap

$1.59B

MomentumView details →

1D Return

−3.88%

YTD Return

−39.65%

RSI (14)

24.3

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.7x

Market Cap

$1.59B

RSI (14)

24.3

MomentumView details →

1D Return

−3.88%

YTD Return

−39.65%

ProfitabilityView details →

Gross Margin

92.15%

Net Margin

−3644.21%

EBITDA Margin

−3579.24%

ROE (TTM)

−41.10%

ROA (TTM)

−36.84%

Asset Turnover

0.01x

GrowthView details →

Revenue YoY

−88.87%

EPS YoY

−32.12%

FCF YoY

−15.62%

Revenue CAGR 3Y

−39.71%

EPS CAGR 3Y

+31.64%

EBITDA YoY

−32.52%

EarningsView details →

EPS (Actual)

−$0.52

EPS Surprise

−7.90%

Beats (12Q)

4/12

Next Q EPS Est

−$0.50

Avg Surprise (4Q)

61.19%

Rev Surprise

30.73%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

9.03x

Quick Ratio

9.03x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

7.12M

Net Income (TTM)

−259.50M

Op. CF (TTM)

−143.46M

Next earningsNov 11, 2026 →

Latest newsMore news →

NewAmsterdam Pharma Co N.V. appointed Robert W. Gunning as principal accounting officer, Vice President and Controller, effective August 10, 2026, succeeding Louise Kooij who will depart on August 31, 2026.22d ago

NewAmsterdam Pharma reported Q2 2026 revenue of $3.7 million, down 80.6% year-over-year, and a net loss of $64.1 million.31d ago

Similar companies

Guangzhou Innogen Pharmaceutl Grp Co Ltd02591.HK LB Pharmaceuticals Inc Common StockLBRX SinoMab BioScience Limited03681.HK HighTide Therapeutics Inc02511.HK RAPT Therapeutics, Inc.RAPT SL Science Holding Limited Ordinary SharesSLBT Find similar companies →

Latest newsMore news →

NewAmsterdam Pharma Co N.V. appointed Robert W. Gunning as principal accounting officer, Vice President and Controller, effective August 10, 2026, succeeding Louise Kooij who will depart on August 31, 2026.22d ago NewAmsterdam Pharma reported Q2 2026 revenue of $3.7 million, down 80.6% year-over-year, and a net loss of $64.1 million.31d ago NewAmsterdam Pharma Co N.V. elected John W. Smither and Janneke van der Kamp as non-executive directors, effective June 2, 2026.94d ago